The use of inflammatory bowel disease medications in the treatment of enteritis/rejection after intestinal transplantation
Background: Allograft rejection (AR) and enteritis after intestinal transplantation (ITx) have been challenging. The use of inflammatory bowel disease (IBD) drugs (Infliximab, Adalimumab, or Vedolizumab) to treat AR/enteritis have been infrequently reported. Herein we review our experience with IBD drug after ITx.
Authors
- Robert S. Venick (ORCID: https://orcid.org/0000-0002-0956-3147)
- Carolyn Smullin (ORCID: https://orcid.org/0000-0002-0794-5790)
- Douglas G. Farmer (ORCID: https://orcid.org/0000-0001-9080-0527)
- Scarlet Lee
- Yvette Gollaz
- Longgang Yu (ORCID: https://orcid.org/0000-0001-8498-5182)
- Maleche-Obimbo Elizabeth
- Justin Centino
Institutions
- UCLA Health (US)
Publication Details
- Journal
- Intestinal failure.
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.intf.2025.100269
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 0.00